KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $88.1 million.

  • Jazz Pharmaceuticals' Share-based Compensation rose 47.46% to $88.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $290.5 million, marking a year-over-year increase of 25.86%. This contributed to the annual value of $248.0 million for FY2024, which is 9.35% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Share-based Compensation of $88.1 million as of Q3 2025, which was up 36.63% from $64.5 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Share-based Compensation high stood at $88.1 million for Q3 2025, and its period low was $34.5 million during Q1 2021.
  • Its 3-year average for Share-based Compensation is $63.2 million, with a median of $61.4 million in 2023.
  • In the last 5 years, Jazz Pharmaceuticals' Share-based Compensation surged by 75.38% in 2021 and then decreased by 14.00% in 2023.
  • Jazz Pharmaceuticals' Share-based Compensation (Quarterly) stood at $53.1 million in 2021, then climbed by 15.89% to $61.6 million in 2022, then declined by 14.00% to $52.9 million in 2023, then surged by 32.58% to $70.2 million in 2024, then surged by 47.46% to $88.1 million in 2025.
  • Its Share-based Compensation stands at $88.1 million for Q3 2025, versus $64.5 million for Q2 2025 and $67.7 million for Q1 2025.